Browse by category

FDA clears IND and first patient dosed in Alveus’ phase 1b trial of ALV-100 for obesity

The FDA has cleared Alveus Therapeutics’ Investigational New Drug (IND) application for ALV-100, the company’s lead investigational therapy for chronic weight management, enabling initiation of a Phase 1b clinical study. The first patient was dosed last week. ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to address long-term weight management and tol

Ring-augmented SG betters standard SG for greater weight-loss durability at 36 months

14 hours ago

First participants dosed in Ascletis’ 13-week US Phase II Study for ASC30

2 days ago

FDA clears IND and first patient dosed in Alveus’ phase 1b trial of ALV-100 for obesity

2 days ago

Browse by category

FDA clears IND and first patient dosed in Alveus’ phase 1b trial of ALV-100 for obesity

Browse by tag

Ring-augmented SG betters standard SG for greater weight-loss durability at 36 months

First participants dosed in Ascletis’ 13-week US Phase II Study for ASC30

FDA clears IND and first patient dosed in Alveus’ phase 1b trial of ALV-100 for obesity

Back to Top